PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

74 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Diehl, C. et al.: Dose reduction to motor structures in adjuvant fractionated stereotactic radiotherapy of brain metastases: nTMS-derived DTI-based motor fiber tracking in treatment planning. Cancers 15:282 (2023)
2.
Diehl, C. et al.: Low-energy X-ray intraoperative radiation therapy (Lex-IORT) for resected brain metastases: A single-institution experience. Cancers 15:14 (2023)
3.
Blandino, A.* et al.: Identification of circulating lncRNAs associated with gallbladder cancer risk by tissue-based preselection, cis-eQTL validation, and analysis of association with genotype-based expression. Cancers 14:634 (2022)
4.
Dumont, M.* et al.: Uncovering the contribution of moderate-penetrance susceptibility genes to breast cancer by whole-exome sequencing and targeted enrichment sequencing of candidate genes in women of European ancestry. Cancers 14:3363 (2022)
5.
Erlmeier, F.* et al.: MALDI mass spectrometry imaging—prognostic pathways and metabolites for renal cell carcinomas. Cancers 14:1763 (2022)
6.
Gentschev, I.* et al.: Tumor colonization and therapy by Escherichia coli nissle 1917 strain in syngeneic tumor-bearing mice is strongly affected by the gut microbiome. Cancers 14:6033 (2022)
7.
Geppert, J. et al.: Aging aggravates cachexia in tumor-bearing mice. Cancers 14:90 (2022)
8.
Gulde, S. et al.: Combined targeting of pathogenetic mechanisms in pancreatic neuroendocrine tumors elicits synergistic antitumor effects. Cancers 14:5481 (2022)
9.
Hess-Rieger, J. et al.: Integration of p16/HPV DNA status with a 24-miRNA-defined molecular phenotype improves clinically relevant stratification of head and neck cancer patients. Cancers 14:3745 (2022)
10.
Junker, Y.* et al.: As easy as 1, 2, 3? How to determine CBCT frequency in adjuvant breast radiotherapy. Cancers 14:4164 (2022)
11.
Kraus, K.M. et al.: Treatment planning study for microbeam radiotherapy using clinical patient data. Cancers 14:685 (2022)
12.
Kraus, K.M. et al.: Pneumonitis after stereotactic thoracic radioimmunotherapy with checkpoint inhibitors: Exploration of the dose-volume-effect correlation. Cancers 14:2948 (2022)
13.
Küchler, M.* et al.: Outcome after radiotherapy for vestibular schwannomas (VS)-differences in tumor control, symptoms and quality of life after radiotherapy with photon versus proton therapy. Cancers 14:1916 (2022)
14.
Lopez-Millan, B.* et al.: The multi-kinase inhibitor EC-70124 is a promising candidate for the treatment of FLT3-ITD-positive acute myeloid leukemia. Cancers 14:1593 (2022)
15.
Lyu, C.* et al.: Identification of EZH2 as cancer stem cell marker in clear cell renal cell carcinoma and the anti-tumor effect of epigallocatechin-3-gallate (EGCG). Cancers 14:4200 (2022)
16.
Patil, S.* et al.: A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT. Cancers 14:3031 (2022)
17.
Sailer, N.* et al.: T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity. Cancers 14:1998 (2022)
18.
Schültke, E.* et al.: Good Timing Matters: The spatially fractionated high dose rate boost should come first. Cancers 14:5964 (2022)
19.
Tanno, B.* et al.: MiRNA-mediated fibrosis in the out-of-target heart following partial-body irradiation. Cancers 14:3463 (2022)
20.
Trassl, L. & Stathopoulos, G.T.: KRAS pathway alterations in malignant pleural mesothelioma: An underestimated player. Cancers 14:4303 (2022)